

## Boule appoints Holger Lembrér as CFO

Boule Diagnostics AB appoints Holger Lembrér as new CFO to take office in January 2024.

Holger has a long career in various senior finance positions within the ASSA ABLOY Group. He has a solid financial foundation from being CFO for a business area, responsible for investor relations and Financial Controller for the group. He has implemented profitability improvements and driven strategic projects with great success. Holger has also worked as an accountant at EY and is currently CFO for Oncopeptides.

"I am really looking forward to becoming part of the team at Boule and working together to continue developing the company forward. It feels inspiring to join a company with long experience, expertise, and strong brands in its industry," says Holger Lembrér.

"I am convinced that Holger will contribute with new perspectives and strengthen the management at Boule, with his experience from a reputable listed company with its own manufacturing and global sales," says President and CEO Jesper Söderqvist.

Current interim CFO Jan Benjaminson will continue in his role until Holger Lembrér takes over in early 2024.

## For more information, please contact:

Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90 Jan Benjaminson, CFO, Boule Diagnostics AB, phone +46 (0)70-666 93 88

## About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule's own local sales and support personnel. The Boule shares have been listed on Nasdaq Stockholm since 2011. <a href="https://www.boule.com">www.boule.com</a>

This information is information that Boule Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on June 14, 2023.